title: The display of sexual behaviors by female rats administered ICI 182,780.
abstract: ICI 182,780 (ICI) is a pure antiestrogen that when administered systemically does not cross the blood-brain barrier, thus its actions are limited to the periphery. Four experiments were conducted to test the effects of ICI on the display of sexual behaviors in ovariectomized rats. Experiment 1 examined the effects of three doses of ICI (250, 500, and 750 micro g/rat) on sexual receptivity and paced mating behavior in rats primed with estradiol benzoate (EB) in combination with progesterone (P). Experiments 2 and 3 compared the display of sexual behaviors in rats primed with EB+P or EB alone and administered either 250 micro g ICI (Experiment 2) or 500 micro g ICI (Experiment 3). Experiment 4 tested the effects of ICI (250 and 500 micro g) on the expression of estrogen-induced progestin receptors in the uterus. ICI did not affect the display of sexual receptivity in any experiment. In rats primed with EB+P, paced mating behavior was altered by the 500 and 750 micro g, but not the 250 micro g, doses of ICI. The lowest (250 micro g) dose of ICI did alter paced mating behavior in rats primed with EB alone. The effects of ICI on paced mating behavior were manifested by a substantial lengthening of contact-return latencies following intromissions and ejaculations. The percentage of exits were not affected by ICI. Estrogen stimulation of uterine weight and induction of uterine progestin receptors was suppressed by ICI (250 and 500 micro g). ICI effects on paced mating behavior in hormone-primed female rats are likely to reflect antiestrogenic actions in the periphery, including interference with the estrogen induction of progestin receptors.
authors.affiliation: Department of Psychological and Brain Sciences, 6207 Moore Hall, Dartmouth College, Hanover, NH 03755, USA. ann.clark@dartmouth.edu
authors.forename: Ann S
authors.initials: AS
authors.lastname: Clark
authors.forename: Fay A
authors.initials: FA
authors.lastname: Guarraci
authors.forename: Alison B
authors.initials: AB
authors.lastname: Megroz
authors.forename: Donna M
authors.initials: DM
authors.lastname: Porter
authors.forename: Leslie P
authors.initials: LP
authors.lastname: Henderson
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology*; D004965:Estrogen Antagonists / Q000494:pharmacology*; D005260:Female; D000077267:Fulvestrant; D008297:Male; D009929:Organ Size; D010052:Ovariectomy; D011374:Progesterone / Q000494:pharmacology; D051381:Rats; D020318:Rats, Long-Evans; D011930:Reaction Time / Q000187:drug effects; D012726:Sexual Behavior, Animal / Q000187:drug effects*; D014599:Uterus / Q000033:anatomy & histology
chemical_list: D004965:Estrogen Antagonists; C074283:estradiol 3-benzoate; D000077267:Fulvestrant; D011374:Progesterone; D004958:Estradiol